Zusammenfassung
Adenosindiphosphat (ADP)-induzierte Plättchenaktivierung
spielt eine entscheidende Rolle bei der Bildung des thrombotischen
Gefäßverschlusses und der Pathogenese der koronaren Herzerkrankung.
Die duale Thrombozytenaggregationshemmung mit den ADP-Rezeptor-Antagonisten
wie Clopidogrel in Kombination mit Aspirin gilt inzwischen als Standardtherapie
nach erfolgter Stentimplantation. Der vorliegende Beitrag gibt eine Übersicht über
die aktuellen Entwicklungen auf dem Gebiet der ADP-Rezeptor-Antagonisten.
Abstract
Adenosine diphosphate (ADP)-induced platelet activation plays
a pivotal role in the thrombocyte aggregation and pathogenesis of
ischemic heart disease. The long-term benefit of dual anti-platelet
therapy with ADP-receptor antagonists, such as clopidogrel, in combination
with aspirin is well established for patients following coronary stent
implantation. This review discusses latest developments in the field
of ADP-receptor antagonists.
Schlüsselwörter
Thienopyridine - Ticagrelor - Cangrelor - akutes Koronarsyndrom
Keywords
thienopyridines - ticagrelor - cangrelor - acute coronary syndrome
Literatur
- 1
A randomised, blinded,
trial of clopidogrel versus aspirin in patients at risk of ischaemic
events (CAPRIE). CAPRIE Steering Committee.
Lancet.
1996;
348
1329-1339
- 2
Angiolillo D J, Guzman L A.
Clinical overview
of promising nonthienopyridine antiplatelet agents.
Am
Heart J.
2008;
156
S23-28
- 3
Banerjee S, Weideman R A, Weideman M W. et al .
Effect of concomitant use
of clopidogrel and proton pump inhibitors after percutaneous coronary
intervention.
Am J Cardiol.
2011;
107
871-878
- 4
Bhatt D L, Cryer B L, Contant C F. et al .
Clopidogrel with or without
omeprazole in coronary artery disease.
N Engl J Med.
2010;
363
1909-1917
- 5
Bhatt D L, Lincoff A M, Gibson C M. et al .
Intravenous platelet blockade with
cangrelor during PCI.
N Engl J Med.
2009;
361
2330-2341
- 6
Brandt J T, Close S L, Iturria S J. et al .
Common polymorphisms of CYP2C19
and CYP2C9 affect the pharmacokinetic and pharmacodynamic response
to clopidogrel but not prasugrel.
J Thromb Haemost.
2007;
5
2429-2436
- 7
Brass L F, Manning D R, Cichowski K, Abrams C S.
Signaling through
G proteins in platelets: to the integrins and beyond.
Thromb
Haemost.
1997;
78
581-589
- 8
Cannon C P, Husted S, Harrington R A. et al .
Safety, tolerability, and initial efficacy
of AZD6140, the first reversible oral adenosine diphosphate receptor
antagonist, compared with clopidogrel, in patients with non-ST-segment
elevation acute coronary syndrome: primary results of the DISPERSE-2
trial.
J Am Coll Cardiol.
2007;
50
1844-1851
- 9
Chen Z M, Jiang L X, Chen Y P. et al .
Addition of clopidogrel
to aspirin in 45,852 patients with acute myocardial infarction:
randomised placebo-controlled trial.
Lancet.
2005;
366
1607-1621
- 10
Farid N A, Payne C D, Small D S. et al .
Cytochrome P450 3A inhibition
by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and
pharmacodynamics differently.
Clin Pharmacol Ther.
2007;
81
735-741
- 11
Fischbach W, Darius H, Gross M. et al .
[Concomitant use of platelet aggregation
inhibitors and proton pump inhibitors (PPIs): Position paper of
the German Society for Digestive and Metabolic Diseases (DGVS) and
the German Society of Cardiology (DGK)].
Z Gastroenterol.
2010;
48
1156-1163
- 12
Fuster V, Badimon L, Badimon J J, Chesebro J H.
The pathogenesis
of coronary artery disease and the acute coronary syndromes (2).
N Engl J Med.
1992;
326
310-318
- 13 Gawaz M P. Das Blutplättchen. Stuttgart: Georg Thieme; 1999 23: 29-36
- 14
Gent M, Blakely J A, Easton J D. et al .
The Canadian American Ticlopidine Study
(CATS) in thromboembolic stroke.
Lancet.
1989;
1
1215-1220
- 15
Hass W K, Easton J D, Adams Jr H P. et al .
A randomized trial
comparing ticlopidine hydrochloride with aspirin for the prevention
of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study
Group.
N Engl J Med.
1989;
321
501-507
- 16
Hechler B, Eckly A, Ohlmann P, Cazenave J P, Gachet C.
The P2Y1 receptor, necessary but not sufficient to support full
ADP-induced platelet aggregation, is not the target of the drug
clopidogrel.
Br J Haematol.
1998;
103
858-866
- 17
Husted S, Emanuelsson H, Heptinstall S. et al .
Pharmacodynamics, pharmacokinetics, and
safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin
in patients with atherosclerosis: a double-blind comparison to clopidogrel
with aspirin.
Eur Heart J.
2006;
27
1038-1047
- 18
Jantzen H M, Gousset L, Bhaskar V. et al .
Evidence for two distinct G-protein-coupled
ADP receptors mediating platelet activation.
Thromb Haemost.
1999;
81
111-117
- 19
Janzon L, Bergqvist D, Boberg J. et al .
Prevention of myocardial infarction and
stroke in patients with intermittent claudication; effects of ticlopidine.
Results from STIMS, the Swedish Ticlopidine Multicentre Study.
J Intern Med.
1990;
227
301-308
- 20
Lima J P, Brophy J M.
The potential
interaction between clopidogrel and proton pump inhibitors: a systematic
review.
BMC Med.
2010;
8
81
- 21
Mega J L, Close S L, Wiviott S D. et al .
Cytochrome p-450 polymorphisms and
response to clopidogrel.
N Engl J Med.
2009;
360
354-362
- 22
Mega J L, Close S L, Wiviott S D. et al .
Cytochrome P450 genetic
polymorphisms and the response to prasugrel: relationship to pharmacokinetic,
pharmacodynamic, and clinical outcomes.
Circulation.
2009;
119
2553-2560
- 23
Mehta S R, Yusuf S, Peters R J. et al .
Effects of pretreatment with clopidogrel
and aspirin followed by long-term therapy in patients undergoing
percutaneous coronary intervention: the PCI-CURE study.
Lancet.
2001;
358
527-533
- 24
Sabatine M S, Cannon C P, Gibson C M. et al .
Addition of clopidogrel
to aspirin and fibrinolytic therapy for myocardial infarction with
ST-segment elevation.
N Engl J Med.
2005;
352
1179-1189
- 25
Sugidachi A, Ogawa T, Kurihara A. et al .
The greater in vivo antiplatelet effects
of prasugrel as compared to clopidogrel reflect more efficient generation
of its active metabolite with similar antiplatelet activity to that
of clopidogrel’s active metabolite.
J Thromb
Haemost.
2007;
5
1545-1551
- 26
Wallentin L, Becker R C, Budaj A. et al .
Ticagrelor versus clopidogrel in patients
with acute coronary syndromes.
N Engl J Med.
2009;
361
1045-1057
- 27
Wang T H, Bhatt D L, Topol E J.
Aspirin and clopidogrel resistance: an emerging
clinical entity.
Eur Heart J.
2006;
27
647-654
- 28
Wiviott S D, Braunwald E, Angiolillo D J. et al .
Greater clinical benefit
of more intensive oral antiplatelet therapy with prasugrel in patients with
diabetes mellitus in the trial to assess improvement in therapeutic
outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis
in Myocardial Infarction 38.
Circulation.
2008;
118
1626-1636
- 29
Wiviott S D, Braunwald E, McCabe C H. et al .
Intensive oral antiplatelet therapy for
reduction of ischaemic events including stent thrombosis in patients
with acute coronary syndromes treated with percutaneous coronary
intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis
of a randomised trial.
Lancet.
2008;
371
1353-1363
- 30
Wiviott S D, Braunwald E, McCabe C H. et al .
Prasugrel versus clopidogrel in patients
with acute coronary syndromes.
N Engl J Med.
2007;
357
2001-2015
- 31
Yusuf S, Zhao F, Mehta S R. et al .
Effects of clopidogrel in addition to aspirin
in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med.
2001;
345
494-502
Priv.-Doz. Dr. Natig Gassanov
Herzzentrum Köln
Klinik III für
Innere Medizin
Kerpener Str. 62
50924 Köln
Phone: 0221/478-32354
Fax: 0221/478-32712
Email: Natig.Gassanov@uk-koeln.de
